Thank you, Jon, and good morning, everyone. I’ll provide a more detailed overview of our Q3 2024 financial performance, and then turn it back to Jon before we open the call for questions. Unless stated otherwise, all comparisons and variance commentary are on a year-over-year basis. In Q3, net sales increased by 11% to $107.1 million compared to $96.9 million. As Jon mentioned, the increase was primarily driven by our strong international growth, which more than doubled compared to the prior year, as we continue to see momentum from new products. We also had a solid domestic quarter, even though it was down compared to the year ago period. We expect domestic growth to rebound in the fourth quarter. As mentioned, international sales performed well this quarter, up 13% or $6 million from the prior year. Gross profit for Q3 was up 13% to $26 million compared to $22 million from the prior year, with gross margins of 52% compared to 51% in the prior year. The increase in gross margin was mainly due to favorable product mix and improved product efficiency. Adjusted EBITDA in Q3 increased by 13% to $40 million compared to $35.5 million in the prior year, with an adjusted EBITDA margin of 37.3% compared to 36.7% in the third quarter of 2023. The 69 basis point increase reflects the operating leverage inherent in our business as we drive improved efficiencies and cost management. Adjusted net income, which excludes the impact of non-cash fair value adjustments to the warrants, earn-out, revaluations and stock compensation, was up 18% in Q3 to $26 million. As detailed in our press release today, we reported a GAAP net loss for the quarter, driven entirely by the significant improvement to our stock price during the quarter, which led to a change in the fair value of the warrant liability, earn-out consideration liability and derivative liability. These non-cash value adjustments offset net income by $108 million this quarter compared to a $6 million non-cash benefit in the year ago period. Our adjusted diluted EPS was $0.27 per diluted share and $0.24 per diluted share in the prior year. We always like to provide you with the year-to-date results in addition to the quarter. On Slide 14 and 15, you could see our year-to-date financial results, which reflect our continued growth on the top and bottom line. On that note, and as Jon mentioned earlier, we’ve revised our 2024 guidance. We now expect net sales guidance to range between $418 million to $424 million, adjusted EBITDA guidance to range between $148 million and $151 million. For Q4, the implied adjusted range is $30 million to $33 million, reflecting the investment to build out our M&A capabilities. Separately, Q4 will include one-time non-recurring professional expenses of between $4 million to $6 million, excluded from the adjusted EBITDA rates that I just provided. Turning to the balance sheet. As of September 30, 2024, we had $52.7 million of cash and cash equivalents and total debt of $330 million. This includes $200 million of term loan and $130 million of exchangeable notes. This compares to cash and cash equivalents of $41.2 million and total debt of $340.3 million at December 31, 2023, and cash and cash equivalents of $23.8 million and total debt of $345 million at September 30, 2023. Looking at our leverage ratios, we provide both our overall debt leverage ratio and our bank agreement secured debt leverage ratio as our bank agreement is calculated with slight differences. CompoSecure secured debt leverage ratio was 1.25x at September 30, 2024, compared to 1.39x at December 31, 2023 and 1.48x at September 30, 2023. At September 30, 2024, we had a bank agreement senior secured debt leverage ratio of 1.06 based on a total adjusted senior secured debt of $170 million and trailing 12-month bank adjusted EBITDA of $160 million. This compares to 1.39x at December 31, 2023. We’d like to mention that as a result of our recent refinancing of our credit facility, we’re able to reduce our senior secured indebtedness by cash on hand up to $30 million in this calculation. Now turning to our cash flow statement on Slide 18. You can see that the net cash provided by our operating activities year-to-date was $94 million, up 21% versus the comparable period last year. I also want to take a moment to reiterate the impact of the Resolute Holdings transaction completed on September 17. As a reminder, the selling shareholders exchanged all of their Class B units for Class A shares, and Resolute acquired 49.3 million Class A shares, representing approximately 60% of CompoSecure’s outstanding shares. Therefore, tax distributions to the former unitholders of our subsidiary, LLC, will no longer take place. We will pay taxes at the C corp going forward with the anticipation of approximately $20 million of additional free cash flow per year. At September 30, 2024, CompoSecure had 82.7 million shares outstanding, all of which were Class A shares, with the increase resulting from the Resolute Holdings transaction. I’ll now turn it back to Jon to provide closing remarks.